FindTrial
Sign In

Valutation of the efficacy of Lactobacillus casei subspeciae casei DG in prevention of Crohn s disease relapse after induction of clinical remission by antibiotics a multicentric, randomised, double-blind, placebo-controlled study

Valutation of the efficacy of Lactobacillus casei subspeciae casei DG in prevention of Crohn s disease relapse after induction of clinical remission by antibiotics a multicentric, randomised, double-blind, placebo-controlled study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002418-39-IT
Enrollment
60
Registered
2007-01-22
Start date
2005-10-20
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prevention of Crohn s disease relapse MedDRA version: 6.1 Level: PT Classification code 10011401

Interventions

Trade Name: A07FA01- Organismi produttori di acido lattico ( fermenti lattici ) Product Name: Enterolactis Plus Product Code: DG 01/05 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lactic ac

Sponsors

SOFAR SPA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026